These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 24324582)
1. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. He YF; Zhang MY; Wu X; Sun XJ; Xu T; He QZ; Di W PLoS One; 2013; 8(12):e79769. PubMed ID: 24324582 [TBL] [Abstract][Full Text] [Related]
2. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. Zhang M; He Y; Sun X; Li Q; Wang W; Zhao A; Di W J Ovarian Res; 2014 Feb; 7():19. PubMed ID: 24507759 [TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma]. Wan T; Liu JH; Zheng LM; Cai MY; Ding T Ai Zheng; 2009 Mar; 28(3):323-7. PubMed ID: 19619451 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Yuan X; Zhang J; Li D; Mao Y; Mo F; Du W; Ma X Gynecol Oncol; 2017 Oct; 147(1):181-187. PubMed ID: 28698008 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Rakaee M; Busund LR; Jamaly S; Paulsen EE; Richardsen E; Andersen S; Al-Saad S; Bremnes RM; Donnem T; Kilvaer TK Neoplasia; 2019 Mar; 21(3):282-293. PubMed ID: 30743162 [TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells. Li H; Yang B; Huang J; Lin Y; Xiang T; Wan J; Li H; Chouaib S; Ren G Oncotarget; 2015 Oct; 6(30):29637-50. PubMed ID: 26359357 [TBL] [Abstract][Full Text] [Related]
7. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Reinartz S; Schumann T; Finkernagel F; Wortmann A; Jansen JM; Meissner W; Krause M; Schwörer AM; Wagner U; Müller-Brüsselbach S; Müller R Int J Cancer; 2014 Jan; 134(1):32-42. PubMed ID: 23784932 [TBL] [Abstract][Full Text] [Related]
8. FGF18 as a potential biomarker in serous and mucinous ovarian tumors. El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667 [TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Skírnisdóttir I; Seidal T Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012 [TBL] [Abstract][Full Text] [Related]
12. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472 [TBL] [Abstract][Full Text] [Related]
13. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008 [TBL] [Abstract][Full Text] [Related]
14. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584 [TBL] [Abstract][Full Text] [Related]
15. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720 [TBL] [Abstract][Full Text] [Related]
16. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315 [TBL] [Abstract][Full Text] [Related]
17. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. Imai Y; Yamagishi H; Fukuda K; Ono Y; Inoue T; Ueda Y World J Gastroenterol; 2013 Jul; 19(25):3957-68. PubMed ID: 23840140 [TBL] [Abstract][Full Text] [Related]
18. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D; Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147 [TBL] [Abstract][Full Text] [Related]
19. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. Hanski C; Hofmeier M; Schmitt-Gräff A; Riede E; Hanski ML; Borchard F; Sieber E; Niedobitek F; Foss HD; Stein H; Riecken EO J Pathol; 1997 Aug; 182(4):385-91. PubMed ID: 9306958 [TBL] [Abstract][Full Text] [Related]
20. Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship. Jernigan AM; Mahdi H; Rose PG Int J Gynecol Cancer; 2015 Sep; 25(7):1232-8. PubMed ID: 26067864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]